The drug is commonly used across conditions presenting with systemic or localized discomfort related to mineral balance. This medication is indicated for the management of mineral imbalances such as hypocalcemia associated with hypoparathyroidism and metabolic bone diseases.

This supportive therapy is commonly used across conditions presenting with systemic or localized discomfort, including rickets, osteomalacia, and bone-related conditions associated with chronic kidney stress. It helps address symptoms that create noticeable functional strain, such as the painful spasms of tetany and muscle cramps.

“The main therapeutic benefit contributes to maintaining a sense of stability when mineral levels are more noticeable, which helps support general well-being during symptomatic phases.”

This approach assists with maintaining functional stability and provides supportive relief when patients experience symptoms related to heightened physiological activity.

---

Quick Fact: Relief for Mineral Imbalance Symptoms
Primary Indication Areas	Hypoparathyroidism, Hypocalcemia, Rickets, Osteomalacia
Symptom Relief Focus	Muscle cramps, tetany, twitching, neuromuscular irritability
Patient Benefit	Supports functional stability and eases symptom burden

Official Eligibility and Restrictions

Компливит Аква Д3 (active ingredient: Dihydrotachysterol) is an analogue of Vitamin D. Official regulatory documents define eligibility primarily based on the patient's existing mineral status and certain physiological conditions.

Classification	Population Group	Status in Regulatory Labeling
Contraindicated	Hypercalcemia (high calcium levels)	Absolute Prohibition
Contraindicated	Hypervitaminosis D (excessive Vitamin D)	Absolute Prohibition
Contraindicated	Breastfeeding Mothers	Prohibited
Allowed	Patients with Hypoparathyroidism, Rickets	Established Use
Conditional Use	Patients with Renal Impairment/Calculi	Requires strict caution and monitoring
Conditional Use	Pregnant Patients (Category C)	Only if benefit officially outweighs risk

Use is prohibited for individuals with abnormally high calcium levels (Hypercalcemia) or an excess of Vitamin D (Hypervitaminosis D). The medicine is contraindicated in breastfeeding mothers because the active ingredient is excreted into breast milk. While use is established for pediatric and adult patients with conditions such as Hypoparathyroidism and Rickets, patients with impaired kidney function require close medical supervision due to the increased risk of complications.

Interactions with other medicines and products

The interaction profile of Dihydrotachysterol (the active ingredient in Компливит Аква Д3) is defined by its effects on mineral balance and metabolism, as documented in official regulatory labeling.

---

Formally Documented Interaction Outcomes

Interaction Type	Interacting Medicines/Substances	Regulatory Outcome Statement
Contraindicated	Calcium Supplements	Formal prohibition of co-administration due to additive hypercalcemia risk.
Pharmacodynamic	Thiazide Diuretics	May enhance the calcaemic response, increasing the risk of hypercalcemia.
Pharmacodynamic	Cardiac Glycosides (e.g., Digoxin)	Hypercalcemia may enhance toxic effects, increasing the risk of ventricular arrhythmias.
Pharmacokinetic	Anticonvulsants (e.g., Phenobarbital)	May reduce the drug's effectiveness due to enhanced clearance/metabolism.
Pharmacokinetic	Bile Acid Sequestrants (e.g., Cholestyramine)	May impair absorption, leading to a decrease in serum concentration.
Exposure Altering	Mineral Oil	Interferes with intestinal absorption.

---

Official regulatory sources note that co-administration with other Vitamin D Analogues is associated with an increased risk of hypercalcemia. Additionally, Aluminum Hydroxide concentration may be increased when combined with Dihydrotachysterol. There are no mandatory timing or separation requirements explicitly stated in the regulatory documentation for this product.

How Компливит Аква Д3 Works

Hormonal Activation and Receptor Engagement

The provided Vitamin D3 (cholecalciferol) acts within a domain involving receptor-mediated signaling, requiring a two-step hydroxylation cascade in the liver and kidneys to generate the active hormonal metabolite, Calcitriol (1,25( OH)2 D3). This metabolite functions as a transcription factor by binding to the nuclear Vitamin D Receptor (VDR), initiating a genomic cascade that influences the expression of numerous target genes, which provides the basis for subsequent pathway modulation.

Genomic Regulation of Mineral Transport Pathways

This mechanism directly modifies early molecular steps within the domain of mineral homeostasis. The VDR complex upregulates the synthesis of calcium-binding proteins and transport channels in the intestinal epithelium and renal tubules. This action influences signaling patterns relevant to the homeostatic adjustment of calcium and phosphate concentrations by modifying their absorption and reabsorption dynamics.

Pleiotropic Modulation of Cellular Processes

The VDR's widespread distribution means the mechanism engages systems where targeted pathway adjustment is required beyond skeletal tissues. It influences signaling sequences that impact cells throughout the body, including immune and muscle cells. This engagement influences the differentiation and function of multiple non-skeletal cell types, thereby modulating a wider range of biological activity.

Instruction Map: How to use Компливит Аква Д3 — Administration Guidelines

The administration of Dihydrotachysterol, the active component in Компливит Аква Д3, follows a precise, phased protocol. The route of administration is oral for approved forms, which include the liquid oral solution and tablets. The use of the oral solution requires a calibrated dropper to ensure the precise measurement of the daily dose.

Dosing Schedule and Frequency

The standard approach to using this medicine follows a two-phase treatment schedule with a fixed once daily frequency. Therapy begins with a short-term, higher-dose initiation period intended to achieve rapid stabilization of mineral levels. This period is then followed by a long-term maintenance dose that is lower and sustained over time.

Dosing is highly individualized, reflecting a titration-based regimen that prioritizes the patient’s serum calcium level. The dose is adjusted exclusively based on objective laboratory monitoring, aiming to maintain calcium levels within a specific therapeutic range. Adjustments to the maintenance dose are carried out cautiously over extended intervals, typically every 4 to 8 weeks.

Use-Context Constraints

A key procedural constraint in the use protocol is the requirement for concurrent and adequate calcium intake. This necessitates that the medicine be administered as part of a regimen that supports mineral availability. This structured approach, involving oral intake, a daily frequency, and laboratory-guided dose changes, characterizes the usage of the medicine.

Компливит Аква Д3: Research Evidence Overview

Evidence for Use in Hypoparathyroidism and Managing Hypocalcemia

The research context for Dihydrotachysterol (the active component of Компливит Аква Д3) in managing conditions like hypoparathyroidism and low calcium levels (hypocalcemia) primarily involves a mix of long-term observational studies and non-randomized clinical trials. Researchers utilized these studies to monitor the maintenance of target levels of serum calcium and serum phosphorus, which are key measures of the body's mineral balance. These studies included both adults and children who required ongoing monitoring for this chronic condition.

Findings described in the studies report patterns where serum calcium concentrations were observed within pre-defined target ranges in many enrolled individuals. Research also examined patterns related to changes in acute symptoms, such as tetany (involuntary muscle spasms). Studies monitored how these symptoms evolved during the study period.

---

Evidence for Use in Metabolic Bone Diseases (Rickets and Osteomalacia)

Studies examining Dihydrotachysterol in Metabolic Bone Diseases, such as rickets in children and osteomalacia in adults, include clinical trials and case series. Research has explored the medicine’s use in conditions where symptoms may vary in intensity, particularly those associated with issues like chronic kidney stress. Researchers monitored a range of outcomes, including measurements of alkaline phosphatase, calcium, and phosphate levels, and utilized X-rays or other methods to assess evidence of bone mineralization and healing.

---

What is Still Uncertain About the Research Base

What remains uncertain is the availability of recent, large-scale Randomized Controlled Trials (RCTs) against contemporary alternatives. Furthermore, since much of the long-term data comes from observational settings, there are inherent limitations in drawing deterministic conclusions. Research tends to focus more on biomarker control; comprehensive data on long-term functional status and patient-reported outcomes describing daily functioning remain less characterized.

Key Studies & References

1. WHO Collaborating Centre for Drug Statistics Methodology: Dihydrotachysterol (ATC Code A11CC02)
2. Management of Hypoparathyroidism: A European Multidisciplinary Guideline

Common questions about Компливит Аква Д3 (FAQ)

Q: When should I give Компливит Аква Д3 to my child?

A: The product information generally recommends consulting a healthcare professional to determine the appropriate timing and administration for the child's specific needs. Some recommendations suggest giving it with food to aid absorption, but this is best confirmed by the prescribing health provider.

Q: Is the form of Vitamin D (cholecalciferol) in this product the same as what is made from sun exposure?

A: Yes, the active ingredient, cholecalciferol (Vitamin D3), is the same form of Vitamin D that the body naturally produces when the skin is exposed to sunlight. It is also the form commonly used in dietary supplements.

Q: What are the signs of too much Vitamin D (toxicity)?

A: Excessive intake of Vitamin D can potentially lead to hypercalcemia, which is a high level of calcium in the blood. Signs can include nausea, vomiting, weakness, frequent urination, and in rare cases, more serious issues. If you suspect an overdose, it is advised to seek emergency medical attention immediately.

Q: Can Компливит Аква Д3 cause side effects?

A: While generally considered safe when taken as directed, like any preparation, rare side effects may occur. These are typically associated with very high doses over extended periods. It is recommended to discuss any concerns regarding adverse effects with a healthcare provider.

Storage Requirements

Компливит Аква Д3 (Dihydrotachysterol Oral Solution) must be stored in accordance with regulatory mandates to preserve its stability and potency.

Condition	Requirement
Temperature	Store at a temperature not exceeding 25°C (77°F).
Environmental Protection	Protect from light and moisture; do not freeze.
Container Rule	Keep the medicine in its original container and ensure the container is tightly closed.
Stability	The solution has a defined shelf life of generally six months after the first opening, provided the storage rules are maintained.
Child Safety	The product must be kept out of the reach and sight of children.

Disposal Instructions

Unused or expired Компливит Аква Д3 must not be disposed of in household waste or flushed down the toilet (wastewater). Disposal must strictly follow local requirements for pharmaceutical waste.